A Study of Second- and Later-line Palliative Chemotherapy in Patients With Metastatic Colorectal Cancer.

NCT ID: NCT07263178

Last Updated: 2025-12-04

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 1000 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-11-07
• Study Completion Date: 2029-12-31

Brief Summary

This study aims to comprehensively identify the various treatment patterns of second- or subsequent-line palliative chemotherapy used in patients with metastatic colorectal cancer who have experienced failure of first-line palliative chemotherapy and to evaluate the prognosis of each treatment.

Conditions

Metastatic Colorectal Cancer

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Interventions

Second and later-line palliative chemotherapy

As this is a non-interventional study designed to collect data as part of routine clinical practice, the selection and dosage of medication, treatment period, and whether or not to change it are all based on the clinician's judgment

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients who have signed the informed consent after receiving information about the purpose and method of this study.
• Patients with histologically and radiologically confirmed metastatic colorectal cancer (colorectal cancer) who have evaluable (measurable) lesions.
• Patients scheduled to receive their first second-line palliative chemotherapy following failure of first-line palliative chemotherapy (including those who relapse during or within 6 months after completion of postoperative adjuvant therapy, necessitating palliative chemotherapy).
• Patients who understand the research, are cooperative in the research process, and are deemed capable of participating until the completion date.

Exclusion Criteria

• Female patients who are pregnant, have childbearing potential, or are breastfeeding.
• Has received an investigational product within 4 weeks from the study enrollment or has plans to participate in another clinical trial during the participation of this study.
• Other subjects who are considered inappropriate to participate in this study by the judgment of the investigator.

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Boryung Pharmaceutical Co., Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Samsung Medical Center

Seoul, , South Korea

Site Status: RECRUITING

Countries

South Korea

Central Contacts

Shinyoung Oh

Role: CONTACT

syoh@boryung.co.kr

027088000

Facility Contacts

Seung Tae Kim, M.D., Ph.D.

Role: primary

Other Identifiers

BR-CPT-OS-402

Identifier Type: -

Identifier Source: org_study_id